Medexus Pharmaceuticals Inc.

TSX:MDP Stock Report

Market Cap: CA$95.1m

Medexus Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSX:MDP Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Dec 24BuyCA$15,510Michael MuellerIndividual7,000CA$2.89
06 Dec 24SellCA$10,010Michael MuellerIndividual3,500CA$2.86
19 Sep 24BuyCA$7,500Kenneth d'EntremontIndividual3,000CA$2.50
26 Aug 24BuyCA$12,211Brendon BuschmanIndividual5,000CA$2.44
28 Jun 24BuyCA$10,749Kenneth d'EntremontIndividual6,000CA$1.80
28 Jun 24BuyCA$26,213Brendon BuschmanIndividual15,000CA$1.75
13 Feb 24BuyCA$5,408Benoit GravelIndividual3,200CA$1.69

Insider Trading Volume

Insider Buying: MDP insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MDP?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,009,7914.09%
Individual Insiders2,377,6169.63%
General Public21,314,84686.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 14 shareholders own 13.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.02%
Kenneth d'Entremont
1,486,807CA$5.7m0.61%no data
3.29%
Armistice Capital LLC
812,000CA$3.1m0%0.05%
2.24%
Stephen Nelson
554,280CA$2.1m23.3%no data
0.53%
Perritt Capital Management, Inc.
130,100CA$500.9k-3.7%0.18%
0.39%
Michael Mueller
97,070CA$373.7k0%no data
0.28%
Brendon Buschman
68,311CA$263.0k3.42%no data
0.27%
GoodWood Inc.
66,024CA$254.2k0%6.69%
0.26%
Benoit Gravel
63,532CA$244.6k12.7%no data
0.11%
Richard Labelle
27,005CA$104.0k17.7%no data
0.099%
Harmony Garges
24,412CA$94.0k84.1%no data
0.099%
Menassie Taddese
24,412CA$94.0k84.1%no data
0.084%
Ian Wildgoose Brown
20,634CA$79.4k0%no data
0.045%
Nancy Phelan
11,153CA$42.9k0%no data
0.0067%
The Michael and Carol Mueller Family Foundation, Endowment Arm
1,667CA$6.4k0%100.0%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 01:41
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medexus Pharmaceuticals Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
David MartinBloom Burton & Co.
Tania Armstrong-WhitworthCanaccord Genuity